High Risk QT Prolonging Agents

This page covers all High Risk QT Prolonging Agents drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Potassium voltage-gated channel subfamily H member 2, G protein-activated inward rectifier potassium channel 4, 5-hydroxytryptamine receptor 2A.

Targets

Potassium voltage-gated channel subfamily H member 2 · G protein-activated inward rectifier potassium channel 4 · 5-hydroxytryptamine receptor 2A · Histamine H1 receptor · Voltage-dependent P/Q-type calcium channel subunit alpha-1A · 5-hydroxytryptamine receptor 6 · Carbonic anhydrase 6

Marketed (8)

• Hismanal · Other
• Norpace Cr · Pfizer · Cardiovascular
  Norpace is a sodium channel blocker and a Class 1a anti-arrhythmic agent.
• Sparcin · Infectious Disease
• Orlaam · Roxane · Cardiovascular
• Trisenox · Cephalon · Oncology
• Alimix · Cardiovascular
• Seldane · Infectious Disease
• Org 5730 · Cardiovascular

Patent intelligence

• high risk qt prolonging agents patent landscape — aggregated cliff calendar, attackable patents, originator estates